200 related articles for article (PubMed ID: 26181166)
21. JAMA Oncology Patient Page. The Evolution of a Cancer.
West HJ; Jin JO
JAMA Oncol; 2015 Sep; 1(6):850. PubMed ID: 26247697
[No Abstract] [Full Text] [Related]
22. Immunohistochemistry 2015: Protein correlates of molecular alterations and predictive testing.
Hornick JL
Semin Diagn Pathol; 2015 Sep; 32(5):323-4. PubMed ID: 26250936
[No Abstract] [Full Text] [Related]
23. MRI study identifies three subtypes of glioblastoma.
Brower V
Lancet Oncol; 2015 Oct; 16(13):e484. PubMed ID: 26365415
[No Abstract] [Full Text] [Related]
24. Genomic profiling of brain metastases: current knowledge and new frontiers.
Neagu MR; Gill CM; Batchelor TT; Brastianos PK
Chin Clin Oncol; 2015 Jun; 4(2):22. PubMed ID: 26112808
[TBL] [Abstract][Full Text] [Related]
25. Genetics of pancreatic neuroendocrine tumors: implications for the clinic.
Pea A; Hruban RH; Wood LD
Expert Rev Gastroenterol Hepatol; 2015; 9(11):1407-19. PubMed ID: 26413978
[TBL] [Abstract][Full Text] [Related]
26. Precision cancer medicine: the future is now, only better.
Tsimberidou AM; Eggermont AM; Schilsky RL
Am Soc Clin Oncol Educ Book; 2014; ():61-9. PubMed ID: 24857061
[TBL] [Abstract][Full Text] [Related]
27. Mutational spectrum of adult T-ALL.
Neumann M; Vosberg S; Schlee C; Heesch S; Schwartz S; Gökbuget N; Hoelzer D; Graf A; Krebs S; Bartram I; Blum H; Brüggemann M; Hecht J; Bohlander SK; Greif PA; Baldus CD
Oncotarget; 2015 Feb; 6(5):2754-66. PubMed ID: 25595890
[TBL] [Abstract][Full Text] [Related]
28. Patient-derived cell models as preclinical tools for genome-directed targeted therapy.
Lee JY; Kim SY; Park C; Kim NK; Jang J; Park K; Yi JH; Hong M; Ahn T; Rath O; Schueler J; Kim ST; Do IG; Lee S; Park SH; Ji YI; Kim D; Park JO; Park YS; Kang WK; Kim KM; Park WY; Lim HY; Lee J
Oncotarget; 2015 Sep; 6(28):25619-30. PubMed ID: 26296973
[TBL] [Abstract][Full Text] [Related]
29. Predicting Prognosis in Chronic Lymphocytic Leukemia in the Contemporary Era.
Nabhan C; Raca G; Wang YL
JAMA Oncol; 2015 Oct; 1(7):965-74. PubMed ID: 26181643
[TBL] [Abstract][Full Text] [Related]
30. The Signature Program: Bringing the Protocol to the Patient.
Kang BP; Slosberg E; Snodgrass S; Lebedinsky C; Berry DA; Corless CL; Stein S; Salvado A
Clin Pharmacol Ther; 2015 Aug; 98(2):124-6. PubMed ID: 25810246
[TBL] [Abstract][Full Text] [Related]
31. Somatic alterations as the basis for resistance to targeted therapies.
Blair BG; Bardelli A; Park BH
J Pathol; 2014 Jan; 232(2):244-54. PubMed ID: 24114654
[TBL] [Abstract][Full Text] [Related]
32. The mutational landscape of prostate cancer.
Barbieri CE; Bangma CH; Bjartell A; Catto JW; Culig Z; Grönberg H; Luo J; Visakorpi T; Rubin MA
Eur Urol; 2013 Oct; 64(4):567-76. PubMed ID: 23759327
[TBL] [Abstract][Full Text] [Related]
33. [Predictive biomarkers for tumor-relevant signaling pathways in molecular pathology].
Bonzheim I; Fend F
Pathologe; 2014 Feb; 35(1):93-105. PubMed ID: 24496994
[TBL] [Abstract][Full Text] [Related]
34. Companion diagnostic testing for targeted cancer therapies: an overview.
Fan YS
Genet Test Mol Biomarkers; 2013 Jul; 17(7):515-23. PubMed ID: 23574530
[TBL] [Abstract][Full Text] [Related]
35. Molecular classification and drug response prediction in cancer.
Creighton CJ
Curr Drug Targets; 2012 Nov; 13(12):1488-94. PubMed ID: 22974392
[TBL] [Abstract][Full Text] [Related]
36. Predictive pathology in routine diagnostics of solid tumors.
Lassmann S; Werner M
Histol Histopathol; 2012 Mar; 27(3):289-96. PubMed ID: 22237706
[TBL] [Abstract][Full Text] [Related]
37. Pharmacogenomics of intrinsic and acquired pharmacoresistance in colorectal cancer: Toward targeted personalized therapy.
De Mattia E; Cecchin E; Toffoli G
Drug Resist Updat; 2015 May; 20():39-70. PubMed ID: 26027741
[TBL] [Abstract][Full Text] [Related]
38. Systemic therapies for melanoma brain metastases: which drug for whom and when?
Ramanujam S; Schadendorf D; Long GV
Chin Clin Oncol; 2015 Jun; 4(2):25. PubMed ID: 26112811
[TBL] [Abstract][Full Text] [Related]
39. A precision, personalized approach to the management of bladder cancer.
Apolo AB; Burger M
Curr Opin Urol; 2015 Sep; 25(5):416-7. PubMed ID: 26153639
[No Abstract] [Full Text] [Related]
40. Molecular pathology in therapeutics: where are we now, and where are we going?
Harrison DJ; Faratian D
Curr Drug Targets; 2012 Nov; 13(12):1473-4. PubMed ID: 22974390
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
